Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial
Floquet, Anne × Vergote, Ignace Colombo, Nicoletta Fiane, Bent Monk, Bradley J Reinthaller, Alexander Calvert, Paula Herzog, Thomas J Meier, Werner Kim, Jae-Weon Del Campo, Josep M Friedlander, Michael Pisano, Carmela Isonishi, Seiji Crescenzo, Rocco J Barrett, Catherine Wang, Karrie Mitrica, Ionel du Bois, Andreas #
Gynecologic Oncology vol:136 issue:1 pages:37-42
Analysis of progression-free survival (PFS) as the primary endpoint in advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer (AEOC) trials may be confounded by the difficulty of radiologic evaluation of disease progression and the potential for discrepancy between investigator and blinded independent central assessments. PFS as assessed by local investigator (INV) was the primary endpoint of AGO-OVAR16, a randomized, double-blind trial of pazopanib maintenance therapy in AEOC. To confirm the robustness of the primary analysis, PFS was also evaluated by blinded independent central review (BICR).